Key Takeaways
- Tempus AI revealed plans to purchase cancer diagnostics firm Personalis in an all-cash transaction valued at $1.5 billion, paying $16.25 per share
- Shares of TEM declined 8.8% to close at $47.81 on Monday, breaking beneath the stock’s 50-day moving average of $51.40
- Personalis shares also retreated 9.4% to $13.90, even though the acquisition price represents a 5.6% premium over Friday’s closing figure
- Tempus currently owns 12.5% of Personalis and anticipates finalizing the transaction by late 2026 or in the first quarter of 2027
- Wall Street analysts maintain a “Hold” consensus rating with an average price objective of $68.92; company insiders have divested more than $31 million worth of shares in recent months
On Monday, Tempus AI disclosed its intention to acquire Personalis through an all-cash agreement totaling $1.5 billion. The purchase price of $16.25 per share delivers a 5.6% premium compared to Personalis’ closing price of $15.39 from the previous Friday.
Investors responded negatively to the announcement. TEM shares tumbled 8.8% to settle at $47.81, while Personalis stock declined 9.4% to $13.90. Trading volume surged as both securities experienced significant downward pressure.
The decline sent TEM beneath its 50-day moving average at $51.40 — a technical threshold that many traders monitor closely. The stock has now lost 18% year-to-date and is currently experiencing its fourth consecutive session in negative territory.
According to Tempus, the acquisition will enhance its capacity to serve cancer patients throughout the entire care continuum — from initial diagnosis through treatment phases, ongoing monitoring, and detection of potential recurrence. Given that Tempus already possesses a 12.5% ownership position in Personalis, this transaction represents a strategic consolidation that transforms a minority stake into complete ownership.
Personalis CEO Chris Hall described the transaction as delivering optimal value for shareholders. “After conducting an exhaustive process, we are confident Tempus’ offer provides the most value to our shareholders and the fastest path to bringing Personalis’ industry-leading tests to patients suffering from cancer,” Hall stated.
The companies anticipate completing the acquisition by December 2026 or during the opening months of 2027.
Wall Street Analysts Show Divided Opinions
The stock’s decline hasn’t deterred all analysts from maintaining optimistic views on TEM. BTIG Research continues to rate the stock as a buy with an $80 price objective. TD Cowen similarly maintains a buy recommendation. Conversely, Jefferies carries an underperform rating with a $35 target, while Wall Street Zen recently downgraded the shares to sell.
In total, nine analysts recommend buying TEM, four suggest holding, and two advise selling. The consensus rating stands at “Hold” with an average price target of $68.92 — representing significant upside from current trading levels.
Tempus delivered better-than-expected results in its latest quarterly report. The company reported EPS of -$0.13, surpassing the consensus estimate of -$0.21. Revenue reached $348.12 million, exceeding the projected $345.44 million and representing a 36.1% increase compared to the prior-year period.
Despite revenue growth, the company continues to operate at a loss, posting a negative net margin of 22.2% and a negative return on equity of 53.83%. Analysts project full-year EPS of -$1.35.
Notable Insider Selling Activity
Recent insider transactions have attracted investor attention. CEO Ryan Fukushima divested 33,284 shares on July 8 at a price of $57.39 per share, generating approximately $1.9 million. CFO James Rogers sold 11,529 shares on June 25 at $55.00 per share. Both executives executed these transactions through pre-established Rule 10b5-1 trading plans.
Collectively, company insiders have sold over 616,000 shares valued at approximately $31.75 million during the past quarter. Corporate insiders maintain ownership of 24.26% of outstanding shares.
Among institutional investors, Invesco dramatically increased its position by nearly 2,927% during Q2, purchasing more than 204,000 shares. Cathie Wood’s ARK Invest has also been accumulating shares during recent price weakness.
TEM most recently changed hands at $47.81, giving the company a market capitalization of $8.57 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
